Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice.

While nephrologists often observe reduced hematocrit associated with inhibitors of angiotensin-converting enzyme (ACE), the basis for this effect is not well understood. We now report that two strains of ACE knockout mice have a normocytic anemia associated with elevated plasma erythropoietin levels. (51)Cr labeling of red cells showed that the knockout mice have a normal total blood volume but a reduced red cell mass. ACE knockout mice, which lack tissue ACE, are anemic despite having normal renal function. These mice have increased plasma levels of the peptide acetyl-SDKP, a possible stem cell suppressor. However, they also show low plasma levels of angiotensin II. Infusion of angiotensin II for 2 weeks increased hematocrit to near normal levels. These data suggest that angiotensin II facilitates erythropoiesis, a conclusion with implications for the management of chronically ill patients on inhibitors of the renin-angiotensin system.

[1]  A. Disney,et al.  The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  I. Macdougall The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  I. Wilson,et al.  Erythropoietin receptor activation by a ligand-induced conformation change. , 1999, Science.

[4]  I. Dimopoulou,et al.  Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. , 1999, The American journal of medicine.

[5]  A. Goldfarb-Rumyantzev,et al.  Effect of Angiotensin-Converting Enzyme Inhibitors on Response to Erythropoietin Therapy in Chronic Dialysis Patients , 1998, American Journal of Nephrology.

[6]  B. Bourgeon,et al.  High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  A. Cumano,et al.  Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis , 1998, Cell.

[8]  J. Marine,et al.  Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.

[9]  B. Julian,et al.  Angiotensin II stimulates proliferation of normal early erythroid progenitors. , 1997, The Journal of clinical investigation.

[10]  M. Capecchi,et al.  The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. , 1997, The Journal of clinical investigation.

[11]  M. Perazella,et al.  Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  E. Scheuermann,et al.  Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. , 1996, Kidney international.

[13]  B. Suh,et al.  Effect of captopril in the treatment of erythrocytosis after renal transplantation. , 1996, Transplantation proceedings.

[14]  M. Capecchi,et al.  Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[15]  S. E. Brodie New York, New York, USA , 1996 .

[16]  J. Ménard,et al.  Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. , 1996, The Journal of clinical investigation.

[17]  A. Kliger,et al.  Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  J. Ménard,et al.  Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. , 1995, Circulation.

[19]  B. Berk,et al.  Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor , 1995, Nature.

[20]  J. Hodgin,et al.  A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.

[21]  P Corvol,et al.  Peptidyl dipeptidase A: angiotensin I-converting enzyme. , 1995, Methods in enzymology.

[22]  G. J. Bhat,et al.  Angiotensin II stimulates sis-inducing factor-like DNA binding activity. Evidence that the AT1A receptor activates transcription factor-Stat91 and/or a related protein. , 1994, The Journal of biological chemistry.

[23]  B. Julian,et al.  Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. , 1994, Kidney international.

[24]  D. Bonnet,et al.  Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. , 1993, Blood.

[25]  P. Conlon,et al.  The beneficial effect of enalapril on erythrocytosis after renal transplantation. , 1993, Transplantation.

[26]  H. Eiskjær,et al.  Elevated level of erythropoietin in congestive heart failure Relationship to renal perfusion and plasma renin , 1993, Journal of internal medicine.

[27]  A. Riches,et al.  The mechanism of action of the tetrapeptide Acetyl‐N‐Ser‐Asp‐Lys‐Pro (AcSDKP) in the control of haematopoietic stem cell proliferation , 1992, Cell proliferation.

[28]  B. Julian,et al.  Effects of enalapril on erythrocytosis after renal transplantation. , 1991, Annals of internal medicine.

[29]  C. Créminon,et al.  Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay. , 1990, Biochemical and biophysical research communications.

[30]  O. Nielsen,et al.  Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. , 1990, Scandinavian journal of clinical and laboratory investigation.

[31]  I. Seferyńska,et al.  Erythropoietin production in exhypoxic polycythemic mice. , 1989, The American journal of physiology.

[32]  E. Guittet,et al.  Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. A. Micales,et al.  PHYSIOLOGICAL CHARACTERISTICS OF A , 1989 .

[34]  R. van Furth,et al.  Determination of blood volume in the mouse with 51chromium-labelled erythrocytes. , 1984, Journal of immunological methods.

[35]  J. Melby,et al.  ENALAPRIL (MK-421) AND THE WHITE CELL COUNT AND HAEMATOCRIT , 1982, The Lancet.

[36]  E. L. Green Biology of the laboratory mouse , 1966 .